BSE - Delayed Quote INR
Mangalam Drugs & Organics Limited (MANGALAM.BO)
80.46
-2.21
(-2.67%)
At close: April 25 at 3:29:05 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
3,448,723
3,654,894
--
4,473,672
3,797,965
Cost of Revenue
2,409,670
2,948,192
--
3,486,246
2,821,277
Gross Profit
1,039,053
706,702
--
987,426
976,688
Operating Expense
840,106
696,231
--
599,783
532,221
Operating Income
198,947
10,471
--
387,643
444,467
Net Non Operating Interest Income Expense
-147,575
-138,212
--
-111,618
-87,038
Pretax Income
70,799
-110,732
--
277,329
395,191
Tax Provision
-31,115
-20,015
--
80,755
115,482
Net Income Common Stockholders
101,914
-90,717
--
196,575
279,709
Diluted NI Available to Com Stockholders
101,914
-90,717
--
196,575
279,709
Basic EPS
6.44
-5.73
0.00
12.42
17.67
Diluted EPS
6.44
-5.73
0.00
12.42
17.67
Basic Average Shares
15,821.62
15,828.25
15,828.25
15,828.25
15,828.25
Diluted Average Shares
15,821.62
15,828.25
15,828.25
15,828.25
15,828.25
Rent Expense Supplemental
--
5,493
6,003
8,140
9,848
Total Expenses
3,249,776
3,644,423
--
4,086,029
3,353,498
Net Income from Continuing & Discontinued Operation
101,914
-90,717
--
196,575
279,709
Normalized Income
102,279.40
-90,289.35
--
195,897.38
279,709
Interest Income
--
958
2,971
--
6,224
Interest Expense
113,450
104,087
--
72,024
63,209
Net Interest Income
-147,575
-138,212
--
-111,618
-87,038
EBIT
184,249
-6,645
--
349,353
458,400
EBITDA
341,920
139,863
109,889
451,844
550,153
Reconciled Cost of Revenue
2,409,670
2,948,192
--
3,486,246
2,821,277
Reconciled Depreciation
157,671
74,928
109,889
102,491
91,753
Net Income from Continuing Operation Net Minority Interest
101,914
-90,717
--
196,575
279,709
Total Unusual Items Excluding Goodwill
-522
-522
--
956
--
Total Unusual Items
-522
-522
--
956
--
Normalized EBITDA
342,442
140,385
109,889
450,888
550,153
Tax Rate for Calcs
0
0
--
0
0
Tax Effect of Unusual Items
-156.60
-94.35
--
278.38
--
3/31/2021 - 5/24/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade